Inclusion body myositis triggerred with long-term imatinib use.

Rabia DenizTevfik GüzelbeySanem NarinoğluGizem Şirin KalemŞevket Ali EkmenGökçen Gündoğdu ÜnverengilZeynep Karaali

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

This is the first case of IBM associated with prolonged use of imatinib not reported in the literature so far. Since imatinib is widely used in different conditions, it is important to be aware of even its rare adverse effects. Poor response of IBM to conventional immunosuppressive agents enhances the value of etiology identification to relieve symptoms in addition to supportive care.

Keyphrases

chronic myeloid leukemia
healthcare
systematic review
palliative care
quality improvement
interstitial lung disease
pain management
systemic sclerosis
chronic pain